Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, Ardourel D, Wolfson MF, Debrot S, Mudri S, Kleist K, Griffin LL, Hebb L, Sanderson RJ, Wang N, Seaberg M, Chunyk AG, Yang J, Hong Y, Maria Z, Messenheimer DJ, Holland PM, Peng SL, Rixon MW, Dillon SR. Evans LS, et al. Among authors: peng sl. Arthritis Rheumatol. 2023 Jul;75(7):1187-1202. doi: 10.1002/art.42462. Epub 2023 Apr 19. Arthritis Rheumatol. 2023. PMID: 36705554
ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist.
Adom D, Dillon SR, Yang J, Liu H, Ramadan A, Kushekhar K, Hund S, Albright A, Kirksey M, Adeniyan T, Lewis KE, Evans L, Wu R, Levin SD, Mudri S, Yang J, Rickel E, Seaberg M, Henderson K, Gudgeon CJ, Wolfson MF, Swanson RM, Swiderek KM, Peng SL, Hippen KL, Blazar BR, Paczesny S. Adom D, et al. Among authors: peng sl. Sci Transl Med. 2020 Oct 7;12(564):eaay4799. doi: 10.1126/scitranslmed.aay4799. Sci Transl Med. 2020. PMID: 33028709 Free PMC article.
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Maurer MF, Lewis KE, Kuijper JL, Ardourel D, Gudgeon CJ, Chandrasekaran S, Mudri SL, Kleist KN, Navas C, Wolfson MF, Rixon MW, Swanson R, Dillon SR, Levin SD, Kimbung YR, Akutsu M, Logan DT, Walse B, Swiderek KM, Peng SL. Maurer MF, et al. Among authors: peng sl. Nat Commun. 2022 Apr 4;13(1):1790. doi: 10.1038/s41467-022-29286-5. Nat Commun. 2022. PMID: 35379805 Free PMC article.
Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).
Dillon SR, Evans LS, Lewis KE, Debrot S, Blair TC, Mudri S, Kleist K, Levin SD, Bhandari JG, Garrett L, Wolfson MF, Holland PM, Rixon MW, Peng SL. Dillon SR, et al. Among authors: peng sl. Arthritis Rheumatol. 2023 Aug;75(8):1344-1356. doi: 10.1002/art.42484. Epub 2023 May 9. Arthritis Rheumatol. 2023. PMID: 36862144
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Davies R, Peng SL, Lickliter J, McLendon K, Enstrom A, Chunyk AG, Blanchfield L, Wang N, Blair T, Thomas HM, Smith A, Dillon SR. Davies R, et al. Among authors: peng sl. Clin Transl Sci. 2024 Nov;17(11):e70055. doi: 10.1111/cts.70055. Clin Transl Sci. 2024. PMID: 39494621 Free PMC article. Clinical Trial.
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.
Cavalcante L, Chandana S, Lakhani N, Enstrom A, LeBlanc H, Schmalz J, Lengyel K, Schneider F, Thomas H, Chisamore MJ, Peng SL, Naumovski A, Davar D. Cavalcante L, et al. Among authors: peng sl. J Immunother Cancer. 2024 Aug 13;12(8):e009475. doi: 10.1136/jitc-2024-009475. J Immunother Cancer. 2024. PMID: 39142718 Free PMC article.
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, Voskoboynik M, Sanborn RE, Grewal JS, Narayan A, Patnaik A, Gainor JF, Sznol M, Enstrom A, Blanchfield L, LeBlanc H, Thomas H, Chisamore MJ, Peng SL, Naumovski A. Davar D, et al. Among authors: peng sl. J Immunother Cancer. 2024 Aug 3;12(8):e009474. doi: 10.1136/jitc-2024-009474. J Immunother Cancer. 2024. PMID: 39097413 Free PMC article. Clinical Trial.
344 results